Redbiotec seeks funds for complex protein production

Investment & Partnership opportunity

Redbiotec, a biotechnology start-up from ETH Zurich, is looking for investment and partnership to further its protein machine technology. 

Redbiotec AG, formally called XpresSys, has developed technology which provides rapid production of protein complexes, or protein machines, which are used in disease research and drug development. 

As well as private investment Redbiotic is “also looking to partner up with biotech and pharma companies in the area of drug development,” said Corinne John, co-manager of Redbiotec, in the form of contract research and development.

Proteins in the body work in concert as protein machines, which can be compared to cogwheels in a clockwork mechanism.  Until recently protein production was limited to isolated proteins, so the rapid production of protein machines as they work in cells, using patented MultiBac technology, can advance research on understanding diseases and lead to the development of highly specific medicines against cancer, diabetes or Alzheimer's disease. 

Founded in 2006, Redbiotec won a Venture business plan prize for their work the same year.   The company also markets the technology in the form of kits and licences.